Drug Discovery

Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide

Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.

Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal

Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medications.

SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative

SK bioscience has signed a vaccine technology transfer and manufacturing agreement with Colombia’s state-owned pharmaceutical company VECOL, becoming part of the country’s $260m vaccine localisation initiative.

University of Edinburgh develops cell therapy for liver disease

Scientists at the University of Edinburgh have developed a new cell therapy aiming to provide a potential alternative to liver transplants for patients with advanced liver disease.

AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC

AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to treat metastatic triple-negative breast cancer (TNBC).

Concept Life Sciences and OpenBench partner on drug discovery services

Concept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services targeted at early-stage biotech companies.

Gilead Sciences acquires Tubulis for $5bn

Gilead Sciences has concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn.

FUJIFILM opens new iPSC facility in Madison, US

FUJIFILM Cellular Dynamics has opened a new headquarters and induced pluripotent stem cell (iPSC) manufacturing facility in Madison, Wisconsin, US.

BMS and Anthropic collaborate for Claude implementation

Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations.